Last reviewed · How we verify

other causes of cognitive decline — Treatment Landscape & Competitive Intelligence

other causes of cognitive decline (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating other causes of cognitive decline, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Neuraceq FLORBETABEN Life Molecular Radioactive Diagnostic Agent [EPC] 2025-01-01
Vizamyl FLUTEMETAMOL Ge Healthcare Radioactive Diagnostic Agent [EPC] 2013-01-01
Amyvid FLORBETAPIR Avid Radiopharms Inc Radioactive Diagnostic Agent [EPC] 2013-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Avid Radiopharms Inc · 1 drug in other causes of cognitive decline
  2. Ge Healthcare · 1 drug in other causes of cognitive decline
  3. Life Molecular · 1 drug in other causes of cognitive decline

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in other causes of cognitive decline:

Cite this brief

Drug Landscape (2026). other causes of cognitive decline — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/other-causes-of-cognitive-decline. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing